Focus: Integrated Biosciences applies synthetic biology technology to discover drugs targeting stressed cells across immunology, oncology, neurology, respiratory, and infectious disease indications. The company operates as a pre-revenue or early-stage biotech with minimal public commercial footprint.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
High-risk early-stage biotech with novel technology but recent mass layoffs, anemic hiring, and questionable pipeline governance—suitable only for risk-tolerant scientists seeking equity upside and platform exposure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
NDA-approved diagnostic agent with loss of exclusivity approaching; likely a legacy asset with minimal revenue contribution.
Help build intelligence for Integrated Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Integrated Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent mass layoff of 165 is a critical red flag; combined with one job opening and no financial data, company viability is in serious question.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo